Charles Schwab Investment Management Inc. bought a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 135,323 shares of the company's stock, valued at approximately $2,225,000. Charles Schwab Investment Management Inc. owned about 0.25% of Upstream Bio as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently made changes to their positions in UPB. US Bancorp DE bought a new position in Upstream Bio in the 4th quarter worth approximately $27,000. Rhumbline Advisers acquired a new stake in shares of Upstream Bio in the 4th quarter valued at $275,000. Bank of New York Mellon Corp acquired a new position in shares of Upstream Bio during the fourth quarter valued at $607,000. Finally, Moody Aldrich Partners LLC bought a new position in Upstream Bio in the fourth quarter valued at about $1,229,000.
Upstream Bio Trading Down 3.1 %
NASDAQ:UPB traded down $0.21 on Wednesday, hitting $6.49. 203,018 shares of the stock were exchanged, compared to its average volume of 326,094. Upstream Bio, Inc. has a 52 week low of $5.85 and a 52 week high of $29.46. The business has a 50-day moving average of $8.36.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Stories
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
